PROTEASE INHIBITORS USED IN THE TREATMENT OF HIV+ INDUCE BETA-CELL

用于治疗艾滋病毒的蛋白酶抑制剂诱导β细胞

• 批准号: 8168822
• 负责人: Sheng Zhang
• 金额: $ 1.23万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-10 至 2010-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8168822
• 关键词: Beta Cell; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; HIV; HIV Protease Inhibitors; Incidence; Institution; Life; Metabolic; Protease Inhibitor; Research; Research Personnel; Resources; Source; United States National Institutes of Health; mortality

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Inclusion of HIV protease inhibitors (PIs) in the treatment of people living with HIV+ has markedly decreased mortality but also increased the incidence of metabolic abnormalities, causes of which are not well understood.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 包括HIV蛋白酶抑制剂（PI）在治疗HIV+患者中的死亡率显着降低，但也增加了代谢异常的发生率，其原因尚不清楚。